Jonathan C. Javitt - 22 Aug 2023 Form 4 Insider Report for NRX Pharmaceuticals, Inc. (NRXP)

Role
Chief Scientist, Director, 10%+ Owner
Signature
/s/ Jonathan C. Javitt
Issuer symbol
NRXP
Transactions as of
22 Aug 2023
Net transactions value
+$64,400
Form type
4
Filing time
23 Aug 2023, 09:24:41 UTC
Previous filing
14 Feb 2023
Next filing
24 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NRXP Common Stock Purchase $64,400 +200,000 +137% $0.3220 346,332 22 Aug 2023 Direct
holding NRXP Common Stock 12,599,997 22 Aug 2023 By the Jonathan Javitt Living Trust F1
holding NRXP Common Stock 1,422,000 22 Aug 2023 By the Javitt 2012 Irrevocable Dynasty Trust F2
holding NRXP Common Stock 300,000 22 Aug 2023 By the Jonathan Javitt Donor Advised Fund F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Held by the Jonathan Javitt Living Trust of which the reporting person is the trustee of such trust.
F2 Held by the Javitt 2012 Irrevocable Dynasty Trust of which the reporting person is the grantor of such trust. The reporting person is not a trustee or beneficiary of the Trust, and no beneficiary of the Trust resides in the reporting person's household. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
F3 Held by the Jonathan Javitt Donor Advised Fund of which the reporting person is the primary advisor of such fund.